BR9909786A - Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica - Google Patents

Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica

Info

Publication number
BR9909786A
BR9909786A BR9909786-9A BR9909786A BR9909786A BR 9909786 A BR9909786 A BR 9909786A BR 9909786 A BR9909786 A BR 9909786A BR 9909786 A BR9909786 A BR 9909786A
Authority
BR
Brazil
Prior art keywords
glucocorticosteroid
copd
manufacture
pulmonary disease
chronic obstructive
Prior art date
Application number
BR9909786-9A
Other languages
English (en)
Inventor
Carl Persson
Ralph Brattsand
Stefan Ohlsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR9909786A publication Critical patent/BR9909786A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>"UTILIZAçãO DE UM GLUCOCORTICOSTEROIDE PARA A FABRICAçãO DE UM MEDICAMENTO PARA TRATAR FORMAS BRANDAS / PRECOCES DE COPD (DOENçA PULMONAR OBSTRUTIVA CRÈNICA)"<D> A presente invenção se refere à utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar doença pulmonar obstrutiva crónica (COPD) nos pacientes possuindo um valor de <B>FEV~ 1,0~> 65 %<D> do valor presumido e <B>< 10 %<D> de reversibilidade no teste broncodilatador. A presente invenção se refere adicionalmente a um método para tratamento da COPD nos pacientes possuindo um valor de <B>FEV~ 1,0~> 65 %<D> do valor presumido e <B><10 %<D> de reversibilidade no teste broncodilatador, onde uma quantidade efetiva terapeuticamente de um glucocorticosteroide é administrada ao paciente em necessidade de tal tratamento.
BR9909786-9A 1998-04-20 1999-03-18 Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica BR9909786A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801368A SE9801368D0 (sv) 1998-04-20 1998-04-20 New use
PCT/SE1999/000426 WO1999053926A1 (en) 1998-04-20 1999-03-18 Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)

Publications (1)

Publication Number Publication Date
BR9909786A true BR9909786A (pt) 2000-12-19

Family

ID=20411015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909786-9A BR9909786A (pt) 1998-04-20 1999-03-18 Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica

Country Status (10)

Country Link
EP (1) EP1073441A1 (pt)
JP (1) JP2002512193A (pt)
CN (1) CN1306429A (pt)
AR (1) AR018191A1 (pt)
AU (1) AU3062599A (pt)
BR (1) BR9909786A (pt)
CA (1) CA2329008A1 (pt)
HK (1) HK1038703A1 (pt)
SE (1) SE9801368D0 (pt)
WO (1) WO1999053926A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912534D0 (en) * 1999-05-29 1999-07-28 Glaxo Group Res Ltd Novel prognostic surrogate
AR029189A1 (es) * 1999-11-02 2003-06-18 Smithkline Beecham Corp Uso de un inhibidor de fosfodiesterasa 4 y un corticoesteroide antiinflamatorio en forma combinada, separadamente o separadamente secuencial para la preparacion de un medicamento
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1670482B2 (en) 2003-09-16 2022-06-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient

Also Published As

Publication number Publication date
CA2329008A1 (en) 1999-10-28
SE9801368D0 (sv) 1998-04-20
JP2002512193A (ja) 2002-04-23
HK1038703A1 (zh) 2002-03-28
CN1306429A (zh) 2001-08-01
EP1073441A1 (en) 2001-02-07
AU3062599A (en) 1999-11-08
WO1999053926A1 (en) 1999-10-28
AR018191A1 (es) 2001-10-31

Similar Documents

Publication Publication Date Title
Kuzu et al. The effect of cold on the occurrence of bruising, haematoma and pain at the injection site in subcutaneous low molecular weight heparin
AU684087B2 (en) Use of modafinil for the treatment of sleep apnoea and ventilation problems of central origin
Tong et al. Comparing adductor canal block with local infiltration analgesia in total knee arthroplasty: a prospective, blinded and randomized clinical trial
Myderrizi et al. The hematoma block an effective alternative for fracture reduction in distal radius fractures
Tierney et al. Femoral nerve block with bupivacaine 0.25 per cent for postoperative analgesia after open knee surgery
Cooney Management of Colles’ fractures
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
Elhakim et al. Effects of intraperitoneal lidocaine combined with intravenous or intraperitoneal tenoxicam on pain relief and bowel recovery after laparoscopic cholecystectomy
SE9704833D0 (sv) New formulation
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
Case Haematoma block—a safe method of reducing Colles' fractures
Mohammadi et al. Effects of oral clonidine premedication on hemodynamic status in bimaxillary orthognathic surgery: A double-blind randomized clinical trial
Harper et al. Non-union of Colles' fracture: report of two cases
BR9909786A (pt) Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica
HUP0204089A2 (hu) Eljárás és készítmény magas vérnyomás elleni szerekkel szembeni ellenállás és hasonló állapotok kezelésére
Steinbrook et al. Effects of alkalinization of lidocaine on the pain of skin infiltration and intravenous catheterization
Sharma et al. The effect of intravenous dexamethasone on intraoperative and early postoperative pain in lumbar spine surgery: a randomized double-blind placebo-controlled study
Rodriguez-Navarro et al. Potentiation of local anesthetic activity of neosaxitoxin with bupivacaine or epinephrine: development of a long-acting pain blocker
Sarakatsianou et al. Hemodynamic effects of anesthesia type in patients undergoing laparoscopic transabdominal preperitoneal inguinal hernia repair under spinal vs general anesthesia
Borgeat et al. Nerve injury associated with regional anesthesia
Singh et al. In ear surgeries intravenous dexamethasone preoperatively decreases post operative sore throat after endotracheal intubation in adult patients: a prospective randomized control study
Hawkins et al. The Main Line Accidental Intra-Arterial Drug Injection: A Review of Seven Cases.
Toronto Aerosolized Pentamidine Study (TAPS) Group Acute pulmonary effects of aerosolized pentamidine: a randomized controlled study
Jafarian et al. Efficacy of a modified Bier's block in patients undergoing upper limb bone surgery
Loeser et al. Hirudotherapy attenuates arthritic pain in patients with various chronic pain syndromes: A retrospective analysis

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5O,6O, 7O E 8O ANUIDADES

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.